See Supplemental Patient Information
- Metipranolol may be absorbed systemically and the same adverse reactions observed during systemic use may occur with topical administration
- Severe respiratory and cardiac reactions, including death due to bronchospasm in asthmatic patients, and rarely, heart failure-associated death, have been reported following topical metipranolol administration
- Exercise caution in patients with a history of cardiac failure; discontinue therapy on occurrence of cardiac failure
- Contraindicated in patients with severe COPD; caution should be exercised if the drug is indicated in patients with COPD of mild or moderate severity
- If signs and symptoms suggestive of decreased cerebral blood flow develop during therapy, initiate an alternate therapy
- A gradual withdrawal of beta-adrenergic receptor blocking agents is recommended in patients undergoing elective surgery; also, the effects of these agents can be reversed by using agonists, such as isoproterenol, dopamine, dobutamine or levarterenol, if indicated during surgery
- Metipranolol may mask the signs/symptoms of hyperthyroidism; avoid abrupt withdrawal of the drug as it may precipitate a thyroid storm
- Muscle weakness consistent with certain myasthenic symptoms may be enhanced during therapy
- Patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic, during metipranolol therapy; also, these patients may not respond to the usual epinephrine doses used to treat allergic reactions
Cautions: use cautiously in
Supplemental Patient Information
- Instruct patients not to touch the dropper tip to any surface, including the eye or surrounding structures, in order to prevent contamination
- Advise patients wearing soft contact lenses to remove them prior to administration of the drug and to wait at least 15 minutes after instillation of the eye drops
Pregnancy Category:C
Breastfeeding: Metipranolol eye drops would not be expected to cause any adverse events in the breastfed infants. To substantially reduce infant exposure, place pressure over the tear duct by the corner of the eye for >1 min and remove the excess solution with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 4 May 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Optipranolol 0.3 % SOLN [Bottle] (BAUSCH & LOMB)
5 % = $30.99
15 % = $72.97 - Optipranolol 0.3 % SOLN [Bottle] (BAUSCH & LOMB)
10 % = $42.99
30 % = $120.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
